ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ImmunoGen's antibody-drug conjugate mirvetuximab soravtansine misses main goal of Phase III ovarian cancer study
March 03, 2019ImmunoGen announced Friday that a Phase III study of the experimental antibody-drug conjugate (ADC) mirvetuximab soravtansine in patients with folate receptor (FR) alpha-positive, platinum-resistant ovarian cancer failed to meet its primary endpoint of pr
Pharma Sources Insight January 2025
